Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy
BN Singh, BK Malhotra - Clinical pharmacokinetics, 2004 - Springer
Pharmacokinetic interactions between food and orally administered drugs involve changes
mainly in the absorption and metabolism of a drug, and may have clinical implications. Such …
mainly in the absorption and metabolism of a drug, and may have clinical implications. Such …
Effects of hepatic impairment on the pharmacokinetics of abrocitinib and its metabolites
…, ME Dowty, L Wang, BK Malhotra - The Journal of …, 2021 - Wiley Online Library
Abrocitinib, an oral once‐daily Janus kinase 1 selective inhibitor, is under development for
treatment of atopic dermatitis. This phase 1, nonrandomized, open‐label, single‐dose study (…
treatment of atopic dermatitis. This phase 1, nonrandomized, open‐label, single‐dose study (…
The pharmacokinetics, metabolism, and clearance mechanisms of abrocitinib, a selective Janus kinase inhibitor, in humans
…, S Tripathy, TC Goosen, C Banfield, BK Malhotra… - Drug Metabolism and …, 2022 - ASPET
Abrocitinib is an oral once-daily Janus kinase 1 selective inhibitor being developed for the
treatment of moderate-to-severe atopic dermatitis. This study examined the disposition of …
treatment of moderate-to-severe atopic dermatitis. This study examined the disposition of …
Effects of renal impairment on the pharmacokinetics of abrocitinib and its metabolites
…, L Wang, ME Dowty, BK Malhotra - The Journal of …, 2022 - Wiley Online Library
Abrocitinib, an oral once‐daily Janus kinase 1 selective inhibitor, is under development for
the treatment of atopic dermatitis. This phase 1, nonrandomized, open‐label, single‐dose …
the treatment of atopic dermatitis. This phase 1, nonrandomized, open‐label, single‐dose …
[HTML][HTML] Assessment of the effects of inhibition or induction of CYP2C19 and CYP2C9 enzymes, or inhibition of OAT3, on the pharmacokinetics of abrocitinib and its …
…, JA Winton, N Yin, H Valdez, BK Malhotra - European Journal of …, 2022 - Springer
Background and Objective Abrocitinib is a Janus kinase 1-selective inhibitor for the treatment
of moderate-to-severe atopic dermatitis. Abrocitinib is eliminated primarily by metabolism …
of moderate-to-severe atopic dermatitis. Abrocitinib is eliminated primarily by metabolism …
[HTML][HTML] Population pharmacokinetics of abrocitinib in healthy individuals and patients with psoriasis or atopic dermatitis
J Wojciechowski, BK Malhotra, X Wang… - Clinical …, 2022 - Springer
Background and Objective Abrocitinib is a Janus kinase 1 inhibitor in development for the
treatment of atopic dermatitis (AD). This work characterized orally administered abrocitinib …
treatment of atopic dermatitis (AD). This work characterized orally administered abrocitinib …
A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate …
…, B Setnik, P Meisner, KW Sommerville, BK Malhotra… - Pain, 2015 - journals.lww.com
The objective of this multicenter, double-blind, placebo-controlled, randomized withdrawal
study was to evaluate the efficacy and safety of ALO-02, an abuse-deterrent formulation …
study was to evaluate the efficacy and safety of ALO-02, an abuse-deterrent formulation …
Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone
AG Thombre, SL Shamblin, BK Malhotra… - Journal of Controlled …, 2015 - Elsevier
Ziprasidone, like many BCS Class II drugs with low intrinsic solubility and a strong tendency
to crystallize from supersaturated solutions, presents significant technical challenges when …
to crystallize from supersaturated solutions, presents significant technical challenges when …
[HTML][HTML] The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release …
BK Malhotra, GL Schoenhard, AW de Kater… - Journal of Opioid …, 2015 - wmpllc.org
Objective: Remoxy®(Pain Therapeutics, Inc., Austin, TX) is an abuse-deterrent formulation
of extended-release oxycodone. The effects of renal or hepatic impairment on the …
of extended-release oxycodone. The effects of renal or hepatic impairment on the …
Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users
…, K Matschke, BK Malhotra… - The American Journal …, 2016 - Taylor & Francis
Background: ALO-02, comprising pellets of extended-release oxycodone surrounding
sequestered naltrexone, is intended to deter abuse. Objective: Determine the abuse potential of …
sequestered naltrexone, is intended to deter abuse. Objective: Determine the abuse potential of …